BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $18.00 Price Target at Wedbush

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) had its price target upped by equities researchers at Wedbush from $16.00 to $18.00 in a research note issued on Monday,Benzinga reports. The firm presently has an "outperform" rating on the biotechnology company's stock. Wedbush's target price would indicate a potential upside of 101.23% from the company's previous close. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q1 2026 earnings at $0.18 EPS, Q2 2026 earnings at $0.23 EPS, Q3 2026 earnings at $0.18 EPS, Q4 2026 earnings at $0.25 EPS, FY2026 earnings at $0.84 EPS, FY2027 earnings at $0.79 EPS, FY2028 earnings at $0.96 EPS and FY2029 earnings at $1.07 EPS.

Several other research analysts have also commented on BCRX. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target for the company. Royal Bank Of Canada restated an "outperform" rating and issued a $13.00 price target (up from $11.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Barclays boosted their price objective on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 28th. Finally, JPMorgan Chase & Co. upped their price target on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $16.70.

BioCryst Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ BCRX traded down $0.08 during midday trading on Monday, reaching $8.95. 1,407,127 shares of the company's stock traded hands, compared to its average volume of 3,025,919. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -34.40, a P/E/G ratio of 2.68 and a beta of 1.04. The stock's 50 day simple moving average is $10.03 and its 200-day simple moving average is $8.58. BioCryst Pharmaceuticals has a one year low of $6.02 and a one year high of $11.31.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC increased its holdings in BioCryst Pharmaceuticals by 382.6% in the 1st quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company's stock worth $28,597,000 after buying an additional 3,022,769 shares during the period. Vanguard Group Inc. increased its stake in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after acquiring an additional 1,583,826 shares during the period. Eversept Partners LP increased its stake in shares of BioCryst Pharmaceuticals by 269.9% in the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock worth $14,892,000 after acquiring an additional 1,444,907 shares during the period. Nuveen LLC purchased a new position in shares of BioCryst Pharmaceuticals during the first quarter worth $10,677,000. Finally, Jupiter Asset Management Ltd. lifted its position in BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock valued at $16,117,000 after purchasing an additional 971,040 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.